In the U.S., the generic name for Libtayo in its approved indications is cemiplimab-rwlc, with rwlc as the suffix designated in accordance with Nonproprietary Naming of Biological Products Guidance ...

FDA approves Regeneron's Libtayo for adults with high-risk cutaneous squamous cell carcinoma after surgery and radiation, ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for ...

Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to ...

Where public-health policy is concerned, it makes sense to be conservative. But when we try too hard, we may actually do more harm than good. An egregious example is our policy on low-level ionizing ...

Dräger, an international leader in the fields of medical and safety technology, announced the release of the Dräger X-site Live, a state-of-the-art area monitoring kit for gas and radiation hazard ...

NFPA diamond. Laboratory personnel shall fill in the diamond with the highest hazard number pertaining to their laboratory. Biohazard label and appropriate Biosafety Level (if applicable). UV Light ...

Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence interval: 0.